Trevi Therapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Public
  • Employees
  • 26
Employees
  • Stock Symbol
  • TRVI
Stock Symbol
  • Share Price
  • $1.52
  • (As of Monday Closing)

Trevi Therapeutics General Information

Description

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 195 Church Street
  • 14th Floor
  • New Haven, CT 06510
  • United States
+1 (203) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Trevi Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.52 $1.26 $0.46 - $2.96 $32.6M 25.8M 611K -$1.76

Trevi Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 8,260 5,270 3,743
Revenue 0 0 0 0
EBITDA (33,991) (32,451) (26,821) (20,628)
Net Income (34,943) (32,758) (26,050) (20,545)
Total Assets 31,596 47,131 60,001 10,526
Total Debt 14,502 14,211 356 46
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Trevi Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Trevi Therapeutics‘s full profile, request access.

Request a free trial

Trevi Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Trevi Therapeutics‘s full profile, request access.

Request a free trial

Trevi Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of
Drug Discovery
New Haven, CT
26 As of 2021
00000
000000000 00000

000000

olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
0000 000000000
San Francisco, CA
0 As of 0000
0000
000000000000 0000

00000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000 000000000
Henderson, NV
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Trevi Therapeutics Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adynxx Formerly VC-backed San Francisco, CA 0 0000 000000000000 0000
00000000 000000000 Corporation Henderson, NV 000 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed Salt Lake City, UT 0000 000000000 -
00000 000000000000 Venture Capital-Backed San Diego, CA 00 0000 000000 - 000 0000
00000000 Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 22 competitors. Get the full list »

Trevi Therapeutics Patents

Trevi Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3106995-A1 Treatment of chronic cough, breathlessness and dyspnea Pending 23-Jul-2018 0000000000
AU-2019309913-A1 Treatment of chronic cough, breathlessness and dyspnea Pending 23-Jul-2018 0000000000
EP-3826635-A1 Treatment of chronic cough, breathlessness and dyspnea Pending 23-Jul-2018 0000000000
US-20200022974-A1 Treatment of chronic cough, breathlessness and dyspnea Abandoned 23-Jul-2018 0000000000
EP-3820472-A1 Treatment of the pruritic symptoms of liver disease Pending 11-Jul-2018 A61K31/485
To view Trevi Therapeutics’s complete patent history, request access »

Trevi Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Jennifer Good Chief Executive Officer & Founder
Lisa Delfini Chief Financial Officer, Finance
William Forbes Executive
Thomas Sciascia MD Chief Medical Officer & Founder
You’re viewing 4 of 8 executive team members. Get the full list »

Trevi Therapeutics Board Members (12)

Name Representing Role Since
Anne Vanlent Self Board Member 000 0000
Annie Mitsak Ph.D Self Board Member 000 0000
David Meeker MD Self Chairman & Board Member 000 0000
Dominick Colangelo Self Board Member 000 0000
Edward Mathers New Enterprise Associates Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Trevi Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trevi Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Trevi Therapeutics‘s full profile, request access.

Request a free trial